trial
as of 2026-07-01Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
NCTId NCT03784222
at a glance
Phase 4 · Terminated
Enrollment 102 (actual)
Sponsored by Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Primary completion 2022-11-22
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Terminated
Enrollment
102 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2019-01-22
Primary completion
2022-11-22
Eligibility
ALL · 18 Years · 45 Years
Interventions & indications
Sponsors
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.Lead Sponsor
Investigators
1
Xin Yu, MD.Principal Investigator
Sites
8 total
Beijing, ChinaBeijing, ChinaChangsha, ChinaShanghai, ChinaXi’an, ChinaChengdu, ChinaTianjin, ChinaHangzhou, China
Facts & assertions
4 sourced
Enrollment
102
Phase
PHASE4
Primary Completion Date
2022-11-22
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person